EA
AMPH icon

Evolution Advisers’s Amphastar Pharmaceuticals AMPH Stock Holding History

Evolution Advisers’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+4
New +$81 ﹤0.01% 245

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Evolution Advisers's AMPH Position: Q2 2026 in Review

Evolution Advisers opened a new position in Amphastar Pharmaceuticals (AMPH) in Q2 2026: 4 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #245 among its holdings.

210 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Evolution Advisers held 4 shares of Amphastar Pharmaceuticals worth $0 as of Q2 2026.
  • Amphastar Pharmaceuticals was a new Evolution Advisers position in Q2 2026.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #245 holding.
  • 210 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.